

Resource Summary Report

Generated by [dkNET](#) on Sep 19, 2026

a-Synuclein

RRID:AB_398107

Type: Antibody

Proper Citation

BD Biosciences Cat# 610786, RRID:AB_398107

Antibody Information

URL: http://antibodyregistry.org/AB_398107

Proper Citation: BD Biosciences Cat# 610786, RRID:AB_398107

Target Antigen: Synuclein, alpha

Host Organism: mouse

Clonality: monoclonal

Comments: Immunofluorescence, Western blot

Antibody Name: a-Synuclein

Description: This monoclonal targets Synuclein, alpha

Target Organism: rat, mouse, human

Defining Citation: [PMID:17099894](#)

Antibody ID: AB_398107

Vendor: BD Biosciences

Catalog Number: 610786

Record Creation Time: 20231110T044612+0000

Record Last Update: 20260830T013838+0000

Ratings and Alerts

No rating or validation information has been found for a-Synuclein.

No alerts have been found for a-Synuclein.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 45 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#).

So RWL, et al. (2026) Stochastic misfolding drives the emergence of distinct α -synuclein strains. *Neuron*, 114(11), 1951.

Choi SJ, et al. (2026) α -Synuclein expression is required for somatodendritic dopamine release and immediate early gene induction. *Science advances*, 12(5), eady6978.

Riba J, et al. (2026) Synaptic attenuation by human alpha-synuclein depends on two amino acids in its C-terminal tail. *Neurobiology of disease*, 225, 107437.

Ahammad RU, et al. (2026) Peptide-mediated delivery of an α -synuclein-targeting antisense oligonucleotide: Pharmacokinetics, safety, and central nervous system efficacy in a synucleinopathy model. *Drug metabolism and disposition: the biological fate of chemicals*, 54(6), 100304.

Eubanks E, et al. (2025) Increased burden of rare risk variants across gene expression networks predisposes to sporadic Parkinson's disease. *Cell reports*, 44(5), 115636.

Arnold MR, et al. (2025) Alpha-synuclein regulates nucleolar DNA double-strand break repair in melanoma. *Science advances*, 11(15), eadq2519.

Chemla A, et al. (2025) Parkinson's disease mutant Miro1 causes mitochondrial dysfunction and dopaminergic neuron loss. *Brain : a journal of neurology*.

Spargo TP, et al. (2025) Haploinsufficiency of ITSN1 is associated with a substantial increased risk of Parkinson's disease. *Cell reports*, 44(3), 115355.

Kim Y, et al. (2025) Alpha-Synuclein Phosphomimetic Y39E and S129D Knock-In Mice Show Cytosolic Alpha-Synuclein Localization without Developing Neurodegeneration or Motor Deficits. *eNeuro*, 12(4).

Vidyadhara DJ, et al. (2025) Synaptic vesicle endocytosis deficits underlie GBA-linked cognitive dysfunction in Parkinson's disease and Dementia with Lewy bodies. *bioRxiv : the preprint server for biology*.

Vidyadhara DJ, et al. (2024) Synaptic vesicle endocytosis deficits underlie GBA-linked cognitive dysfunction in Parkinson's disease and Dementia with Lewy bodies. *Research square*.

Lam I, et al. (2024) Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of α -synuclein inclusions. *Neuron*, 112(17), 2886.

Walton S, et al. (2024) Neither alpha-synuclein fibril strain nor host murine genotype influences seeding efficacy. NPJ Parkinson's disease, 10(1), 105.

Praschberger R, et al. (2023) Neuronal identity defines α -synuclein and tau toxicity. Neuron, 111(10), 1577.

Olsen AL, et al. (2023) Nicotine-Mediated Rescue of α -Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila. Movement disorders : official journal of the Movement Disorder Society, 38(2), 244.

Mahoney-Crane CL, et al. (2023) Neuronopathic GBA1L444P Mutation Accelerates Glucosylsphingosine Levels and Formation of Hippocampal Alpha-Synuclein Inclusions. The Journal of neuroscience : the official journal of the Society for Neuroscience, 43(3), 501.

Huh E, et al. (2023) P. mirabilis-derived pore-forming haemolysin, HpmA drives intestinal alpha-synuclein aggregation in a mouse model of neurodegeneration. EBioMedicine, 98, 104887.

Kim MS, et al. (2023) Advanced human iPSC-based preclinical model for Parkinson's disease with optogenetic alpha-synuclein aggregation. Cell stem cell, 30(7), 973.

Ryskalin L, et al. (2022) Occurrence of Total and Proteinase K-Resistant Alpha-Synuclein in Glioblastoma Cells Depends on mTOR Activity. Cancers, 14(6).

Park H, et al. (2022) PAAN/MIF nuclease inhibition prevents neurodegeneration in Parkinson's disease. Cell, 185(11), 1943.